The DOI matches its Crossref record; 63 of the 65 references it cites were found in a registry or an index.
Chimeric Antigen Receptor T-Cell Therapy: What We Expect Soon
Open accessAbstract
The treatment landscape for hematologic malignancies has changed since the recent approval of highly effective chimeric antigen receptor T-cell therapies (CAR-T). Moreover, more than 600 active trials are currently ongoing. However, early enthusiasm should be tempered since several issues are still unsolved and represent the challenges for the coming years. The lack of initial responses and early relapse are some hurdles to be tackled. Moreover, new strategies are needed to increase the safety profile or shorten the manufacturing process during CAR-T cells therapy production. Nowadays, most clinically evaluated CAR-T cells products are derived from autologous immune cells. The use of allogeneic CAR-T cells products generated using cells from healthy donors has the potential to change the scenario and overcome many of these limitations. In addition, CAR-T cells carry a high price tag, and there is an urgent need to understand how to pay for these therapies as many of today’s current payment systems do not feature the functionality to address the reimbursement gap. Finally, the clinical experience with CAR-T cells for solid tumors has been less encouraging, and development in this setting is desirable.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Development of CAR-T cell therapy for solid tumors is more challenging than for hematological malignancies, primarily due to intra-tumor heterogeneity and pro-tumoral activity mediated by the tumor microenvironment.
“Despite all these advantages, the development of CAR-T cell therapy for solid tumors has proven to be more challenging compared to hematological malignancies. This is primarily due to various obstacles, particularly including intra-tumor heterogeneity and pro-tumoral activity mediated by TME [66].”
From The Immune Landscape and Immunotherapeutic Strategies in Platinum-Refractory Testicular Germ Cell Tumors (2024) · cites this paper as [66]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
TIMER2.0 for analysis of tumor-infiltrating immune cells
Li, T., Fu, J., Zeng, Z., Cohen, D., Li, J., Chen, Q., Li, B., & Liu, X. S. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa407 · Cited by 5,249
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1804980 · Cited by 4,112
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
Clonal heterogeneity and tumor evolution: past, present, and the future
McGranahan, N., & Swanton, C. (2017) · Cell · doi:10.1016/j.cell.2017.01.018 · Cited by 2,840
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Munshi, N. C., Anderson, L. D., Shah, N., Madduri, D., Berdeja, J., Lonial, S., Raje, N., Lin, Y., Siegel, D., Oriol, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2024850 · Cited by 2,560 · cited 1×
“8 months, more significant than expected from other available therapies in heavily pretreated R/R MM [21].”
BackgroundAbramson, J. S., Palomba, M. L., Gordon, L. I., Lunning, M. A., Wang, M., Arnason, J., Mehta, A., Purev, E., Maloney, D. G., Andreadis, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31366-0 · Cited by 2,430 · cited 1×
“Several strategies are being pursued to optimize the CAR-T cells product composition, including balancing T-cell subset ratios [19], combining CAR-T cells with lenalidomide [36,37] or Bruton tyrosine kinase (BTK) inhibitors [38].”
MethodLocke, F. L., Ghobadi, A., Jacobson, C. A., Miklos, D. B., Lekakis, L. J., Oluwole, O. O., Lin, Y., Braunschweig, I., Hill, B. T., Timmerman, J. M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30864-7 · Cited by 2,286
KTE-X19 CAR T cell therapy in relapsed or refractory mantle-cell lymphoma
Wang, M., Munoz, J., Goy, A., Locke, F. L., Jacobson, C. A., Hill, B. T., Timmerman, J. M., Holmes, H., Jaglowski, S., Flinn, I. W., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1914347 · Cited by 1,862
Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
Eyquem, J., Mansilla-Soto, J., Giavridis, T., van der Stegen, S. J. C., Hamieh, M., Cunanan, K. M., Odak, A., Gönen, M., & Sadelain, M. (2017) · Nature · doi:10.1038/nature21405 · Cited by 1,831 · cited 1×
“The investigation of adding a suicide gene that monoclonal antibodies may trigger, such as rituximab or cetuximab, or by using the CRISPR/Cas9 genome editing technology to clone a specific CAR construct to the T-cell receptor α constant (TRAC) locus resulting in uniform CAR expression and enhanced T-cell potency, need…”
BackgroundBerdeja, J. G., Madduri, D., Usmani, S. Z., Jakubowiak, A., Agha, M., Cohen, A. D., Stewart, A. K., Hari, P., Htut, M., Lesokhin, A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00933-8 · Cited by 1,756 · cited 1×
“Moreover, the rolling submission of a biologics license application has been completed to support the approval of the investigational ciltacabtageneautoleucel in R/R MM [14].”
BackgroundSommermeyer, D., Hudecek, M., Kosasih, P. L., Gogishvili, T., Maloney, D. G., Turtle, C. J., & Riddell, S. R. (2015) · Leukemia · doi:10.1038/leu.2015.247 · Cited by 890
Spiegel, J. Y., Patel, S., Muffly, L. S., Hossain, N. M., Oak, J. S., Baird, J. H., Frank, M. J., Shiraz, P., Sahaf, B., Craig, J. K., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01436-0 · Cited by 640
Poirot, L., Philip, B., Schiffer-Mannioui, C., Le Clerre, D., Chion-Sotinel, I., Derniame, S., Potrel, P., Bas, C., Lemaire, L., Galetto, R., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3321 · Cited by 605
CAR T cells in solid tumors: challenges and opportunities
Marofi, F., Motavalli, R., Safonov, V. A., Thangavelu, L., Yumashev, A. V., Alexander, M., Shomali, N., Chartrand, M. S., Pathak, Y., Jarahian, M., et al. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-02128-1 · Cited by 582
Shah, N. N., Johnson, B. D., Schneider, D., Zhu, F., Szabo, A., Keever-Taylor, C. A., Krueger, W., Worden, A. A., Kadan, M. J., Yim, S., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1081-3 · Cited by 468
Kim, M. Y., Yu, K., Kenderian, S. S., Ruella, M., Chen, S., Shin, T., Aljanahi, A. A., Schreeder, D. M., Klichinsky, M., Shestova, O. E., et al. (2018) · Cell · doi:10.1016/j.cell.2018.05.013 · Cited by 467
Samur, M., Fulciniti, M., Samur, A. A., Bazarbachi, A. H., Tai, Y., PRABHALA, R. H., Alonso, A., Sperling, A. S., Campbell, T., Petrocca, F., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21177-5 · Cited by 423
Quantifying tumor-infiltrating immune cells from transcriptomics data
Finotello, F., & Trajanoski, Z. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2150-z · Cited by 410
CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?
Wagner, J., Wickman, E., DeRenzo, C. C., & Gottschalk, S. M. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.09.015 · Cited by 392
Benjamin, R., Graham, C., Yallop, D., Jozwik, A., Mirci‐Danicar, O., Lucchini, G., Pinner, D., Jain, N., Kantarjian, H., Boissel, N., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32334-5 · Cited by 383
CD19 CAR T cell product and disease attributes predict leukemia remission durability
Finney, O. C., Brakke, H., Rawlings-Rhea, S., Hicks, R., Doolittle, D., Lopez, M., Futrell, B., Orentas, R. J., Li, D., Gardner, R., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci125423 · Cited by 346
Nishio, N., Diaconu, I., Liu, H., Cerullo, V., Caruana, I., Hoyos, V., Bouchier‐Hayes, L., Savoldo, B., & Dotti, G. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0697 · Cited by 337
Siegler, E. L., & Kenderian, S. S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01973 · Cited by 294
Clinical responses with T lymphocytes targeting malignancy-associated κ light chains
Ramos, C. A., Savoldo, B., Torrano, V., Ballard, B. C., Zhang, H., Dakhova, O., Liu, E., Carrum, G., Kamble, R. T., Gee, A. P., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86000 · Cited by 284
CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells
Legut, M., Dolton, G. M., Mian, A. A., Ottmann, O. G., & Sewell, A. K. (2017) · Blood · doi:10.1182/blood-2017-05-787598 · Cited by 239
Diagnosis Related Groups: Product Line Management within Hospitals
Fetter, R. B., & Freeman, J. L. (1986) · Academy of Management Review · doi:10.5465/amr.1986.4282622 · Cited by 214
Sachdeva, M., Duchateau, P. N., Depil, S., Poirot, L., & Valton, J. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ac119.007558 · Cited by 164
The promise--and peril--of integrated cost systems.
Cooper, R., & Kaplan, R. S. (1998) · PubMed · Cited by 156
Liu, S., Deng, B., Yin, Z., Lin, Y., An, L., Liu, D., Pan, J., Yu, X., Chen, B., Wu, T., et al. (2021) · American Journal of Hematology · doi:10.1002/ajh.26160 · Cited by 131
A Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute Lymphoblastic Leukemia
Martino, M. V., Alati, C., Canale, F. A., Musuraca, G., Martinelli, G., & Cerchione, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042150 · Cited by 120
Self-citationAutomated manufacture of autologous CD19 CAR-T cells for treatment of non-hodgkin lymphoma
Jackson, Z., Roe, A., Sharma, A. A., Lopes, F. B. T. P., Talla, A., Kleinsorge-Block, S., Zamborsky, K., Schiavone, J., Manjappa, S., Schauner, R., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01941 · Cited by 102
CAR-T cell therapy: a potential new strategy against prostate cancer
Schepisi, G., Cursano, M. C., Casadei, C., Menna, C., Altavilla, A., Lolli, C., Cerchione, C., Paganelli, G., Santini, D., Tonini, G., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0741-7 · Cited by 97
Self-citationWorks, M. G., Soni, N., Hauskins, C., Sierra, C., Baturevych, A., Jones, J. C., Curtis, W., Carlson, P., Johnstone, T. G., Kugler, D. G., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-1146 · Cited by 88
Allogeneic CAR T cell therapies for leukemia
Qasim, W. (2019) · American Journal of Hematology · doi:10.1002/ajh.25399 · Cited by 86
Frigault, M. J., Bishop, M. R., Rosenblatt, J. M., O’Donnell, E., Raje, N. S., Cook, D., Yee, A. J., Logan, E. K., Avigan, D., Jakubowiak, A. J., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007210 · Cited by 80
Qin, J., Johnstone, T. G., Baturevych, A., Hause, R. J., Ragan, S. P., Clouser, C. R., Jones, J. C., Ponce, R. A., Krejsa, C. M., Salmon, R. A., et al. (2020) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000307 · Cited by 79
Baird, J. H., Frank, M. J., Craig, J. K., Patel, S., Spiegel, J. Y., Sahaf, B., Oak, J. S., Younes, S. F., Ozawa, M. G., Yang, E., et al. (2020) · Blood · doi:10.1182/blood.2020009432 · Cited by 79
Neelapu, S. S., Rossi, J. M., Jacobson, C. A., Locke, F. L., Miklos, D. B., Reagan, P. M., Rodig, S. J., Lekakis, L. J., Flinn, I. W., Zheng, L., et al. (2019) · Blood · doi:10.1182/blood-2019-126218 · Cited by 75
Leblay, N., Maity, R., Barakat, E., McCulloch, S., Duggan, P. R., Jimenez-Zepeda, V. H., Bahlis, N. J., & Neri, P. E. (2020) · Blood · doi:10.1182/blood-2020-137650 · Cited by 74
Zhao, Y., Liu, D., Sun, R., Zhang, J., Zhou, J., Wei, Z., Xiong, M., Cao, X., Lü, Y., Yang, J., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.605766 · Cited by 73
Banerjee, R. K., Marsal, J., Huang, C., Lo, M., Kambhampati, S., Kennedy, V. E., Arora, S., Wolf, J. L., Martin, T. G., Wong, S. W. K., et al. (2021) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2021.03.004 · Cited by 56
Yan, L., Qu, S., Shang, J., Shi, X., Kang, L., Xu, N., Zhu, M., Zhou, J., Jin, S. L., Yao, W., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.3624 · Cited by 52
Hong, R., Hu, Y., & Huang, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.627764 · Cited by 52
CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma
Martino, M. V., Canale, F. A., Alati, C., Vincelli, I. D., Moscato, T., Porto, G., Loteta, B., Naso, V., Mazza, M., Nicolini, F., et al. (2021) · Cancers · doi:10.3390/cancers13112639 · Cited by 40
Self-citationThe role of allogeneic HSCT after CAR T cells for acute lymphoblastic leukemia
Jacoby, E. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0604-3 · Cited by 39
Wang, Y., Yang, Y., Hong, R., Zhao, H., Wei, G., Wu, W., Xu, H., Cui, J., Zhang, Y., Chang, A. H., et al. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-00371-6 · Cited by 36
Paving the way towards universal treatment with allogenic T cells
Townsend, M. H., Bennion, K. B., Robison, R. A., & O'Neill, K. L. (2020) · Immunologic Research · doi:10.1007/s12026-020-09119-7 · Cited by 29
Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia
Tettamanti, S., Rotiroti, M. C., Attianese, G. M. P. G., Arcangeli, S., Zhang, R., Banerjee, P., Galletti, G., McManus, S. D., Mazza, M., Nicolini, F., et al. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2043299 · Cited by 26
Self-citationMartino, M. V., Console, G., Russo, L., Meliadò, A., Meliambro, N., Moscato, T., Irrera, G., Messina, G., Pontari, A., & Morabito, F. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.05.018 · Cited by 23
Self-citationLiang, A., Ye, S., Li, P., Huang, J., Zhu, S., Yao, X., Zhou, L., Xu, Y., Zhu, J., Zheng, C., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.2508 · Cited by 22
Zhang, M., & Huang, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.611710 · Cited by 21
Yang, J., He, J., Zhang, X., Wang, Z., Zhang, Y., Cai, S., Sun, Z., Ye, X., He, Y., Shen, L., et al. (2019) · Blood · doi:10.1182/blood-2019-121751 · Cited by 20
Lu, P., Lu, X., Zhang, X., Xiong, M., Zhang, J., Zhou, X., Qi, F., Yang, J., & He, T. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.3041 · Cited by 16
A Characterization of Bridging Therapies Leading up to Commercial CAR T-Cell Therapy
Nasta, S. D., Hughes, M. E., Namoglu, E. C., Landsburg, D. J., Chong, E. A., Barta, S. K., Frey, N. V., Gerson, J. N., Maity, A. M., Plastaras, J. P., et al. (2019) · Blood · doi:10.1182/blood-2019-131399 · Cited by 16
BCMA-targeting approaches for treatment of multiple myeloma
Chen, Y., Nagarajan, C., Tan, M. S. Y., Martinelli, G., & Cerchione, C. (2021) · Panminerva Medica · doi:10.23736/s0031-0808.20.04121-x · Cited by 8
Self-citationKillock, D. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0379-x · Cited by 8
Frigault, M. J., O’Donnell, E., Raje, N. S., Cook, D., Yee, A. J., Rosenblatt, J. M., Gibson, C., Logan, E. K., Avigan, D., Bishop, M. R., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.8015 · Cited by 7
Shah, B. D., Ghobadi, A., Oluwole, O. O., Logan, A. C., Boissel, N., Cassaday, R. D., Forcade, É., Bishop, M. R., Topp, M. S., Tzachanis, D., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.7002 · Cited by 7
CAR T cells targeting options in the fight against multiple myeloma
Nicolini, F., Bravaccini, S., Mazza, M., Gruszka, A., Tazzari, M., Martín-Antonio, B., Juan, M., Ibrahim, T., Maltoni, R., Martinelli, G., et al. (2021) · Panminerva Medica · doi:10.23736/s0031-0808.20.04146-4 · Cited by 5
Self-citationCancer T-cell therapy: building the foundation for a cure
Kamb, A., & Go, W. Y. (2020) · F1000Research · doi:10.12688/f1000research.27217.1 · Cited by 3
Role of anakinra in the management of icans after CAR T-cell therapy for lymphoma.
Munugala, N., Dashkevych, U., & Husnain, M. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.16_suppl.e19506 · Cited by 3
Flagged first, then by citations
2 of the 65 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
CAR T-Cell Persistence Correlates with Improved Outcome in Patients with B-Cell Lymphoma
Wittibschlager, V., Bacher, U., Seipel, K., Porret, N. A., Wiedemann, G., Haslebacher, C., Hoffmann, M., Daskalakis, M., Akhoundova, D., & Pabst, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065688 · Cited by 91
CAR-T cell therapy for hematological malignancies: History, status and promise
Wang, C., Wang, J., Che, S., & Hai, Z. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e21776 · Cited by 64
Enhancing precision in cancer treatment: the role of gene therapy and immune modulation in oncology
Youssef, E. M., Fletcher, B., & Palmer, D. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2024.1527600 · Cited by 61
Schepisi, G., Gianni, C., Cursano, M. C., Gallá, V., Menna, C., Casadei, C., Bleve, S., Lolli, C., Martinelli, G., Rosti, G., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1118610 · Cited by 27
Self-citationAdvances in reprogramming of energy metabolism in tumor T cells
Xuekai, L., Yan, S., Chu, J., Yifei, S., Wu, X., Wenyuan, Z., Han, S., & Xi, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1347181 · Cited by 22
CAR-T cell therapies: patient access and affordability solutions
Gonçalves, E. (2025) · Future Science OA · doi:10.1080/20565623.2025.2483613 · Cited by 21
Biomarkers for Salvage Therapy in Testicular Germ Cell Tumors
Urbini, M., Bleve, S., Schepisi, G., Menna, C., Gurioli, G., Gianni, C., & Giorgi, U. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316872 · Cited by 12
Evmorfopoulos, K., Marsitopoulos, K., Karachalios, R., Karathanasis, A., Dimitropoulos, K., Tzortzis, V., Zachos, I., & Vlachostergios, P. J. (2024) · Cancers · doi:10.3390/cancers16020428 · Cited by 11
“This is primarily due to various obstacles, particularly including intra-tumor heterogeneity and pro-tumoral activity mediated by TME [66].”
BackgroundFarahani, H., Darvishvand, R., Khademolhosseini, A., & Erfani, N. (2024) · Andrology · doi:10.1111/andr.13751 · Cited by 6
Canale, F. A., Martino, M. V., Porto, G., Verduci, C., Console, G., Irrera, G., Loteta, B., Naso, V., Pugliese, M., Moscato, T., et al. (2023) · Supportive Care in Cancer · doi:10.1007/s00520-023-07811-6 · Cited by 6
Self-citationDo CAR-T and Allogeneic Stem Cell Transplant Both Have a Place in Lymphoid Neoplasms?
Martino, M. V., Canale, F. A., Naso, V., Porto, G., Gerace, D. G., & Allegra, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021045 · Cited by 5
Self-citationBayesian network analysis of risk classification strategies in the regulation of cellular products
Jia, G., Lixia, F., Wang, L., Yao, D., & Cui, Y. (2024) · Artificial Intelligence in Medicine · doi:10.1016/j.artmed.2024.102937 · Cited by 2
Harnessing γδ T cells for B7-H3-targeting CAR therapy to enhance anti-tumor therapy in glioblastoma
Wu, H., Chen, T., Yu, Y., & Zhu, S. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-07994-6 · Cited by 1
Neue Therapiestrategien beim primären Lymphom des Zentralnervensystems
Seidel, S., Kaulen, L. D., & von Baumgarten, L. (2023) · Der Nervenarzt · doi:10.1007/s00115-023-01561-w
Yang, L., He, J., Liu, J., Xie, T., & Tang, Q. (2024) · Current Research in Translational Medicine · doi:10.1016/j.retram.2024.103442
Neue Therapiestrategien beim primären ZNS-Lymphom
Seidel, S., Kaulen, L. D., & von Baumgarten, L. (2025) · InFo Hämatologie + Onkologie · doi:10.1007/s15004-025-0920-2
Quality of Life in CAR-T Cell Therapy
Alati, C., Pitea, M., Porto, G., Policastro, G., Bilardi, E., Utano, G., Giordano, L., Sgarlata, A., Delfino, I. M., Idato, A., et al. (2026) · Hematology Reports · doi:10.3390/hematolrep18030040
Self-citationLi, P., Xue, X., & Zhang, Z. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1861111
Metadata
- Authors
- Martino, M., Naso, V., Loteta, B., Canale, F. A., Pugliese, M., Alati, C., Musuraca, G., Nappi, D., Gaimari, A., Nicolini, F., Mazza, M., Bravaccini, S., Derudas, D., Martinelli, G., & Cerchione, C.
- Affiliations
- Azienda ospedaliera "Bianchi-Melacrino-Morelli" (IT)
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IT)
- Ospedale di Bolzano (IT)
- S.C. di Ematologia e C.T.M.O., Ospedale Oncologico di Riferimento Regionale “A. Businco”, 09121 Cagliari, Italy
- Corresponding author
- Nicolini, Fabio
- Cerchione, Claudio
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-11-01
- Volume
- 23
- Issue
- 21
- Pages
- 13332
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC9657035
- OpenAlex
- W4307862496
- Cited by
- 17
- References
- 65
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 5 · 2023: 7
- FWCI
- 0.46
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- CAR T-cell therapy, hematologic malignancies, allogeneic CAR T cells, autologous CAR T cells, early recurrence, CAR-T manufacturing, CAR-T safety, solid tumors, clinical trial challenges
- MeSH terms
- Receptors, Chimeric Antigen, Humans, Neoplasm Recurrence, Local, Neoplasms, Receptors, Antigen, T-Cell, T-Lymphocytes, Immunotherapy, Adoptive, Cell- and Tissue-Based Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
